Clinical trials: SARS-CoV-2
Covid19
Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19
The purpose of this trial is to assess the safety and toxicity profile of the combination of famotidine and oral n-acetyl cysteine in adult outpatients with newly diagnosed SARS-CoV-2 infection.
- Trial name
- NCT04545008
- Testing
- Famotidine, N-Acetyl cysteine
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Prisma Health-Upstate
SARS (Disease)
Cyclosporine For The Treatment Of COVID-19(+)
Phase IIa clinical trial in which 75 non-ICU hospital inpatients will be randomized 2:1 to 7 days of an oral formulation of cyclosporine, Neoral (2.5mg/kg PO BID) + standard of care (SOC) or no Neoral + SOC.
- Trial name
- NCT04492891
- Testing
- Cyclosporine, Standard of Care Treatment
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Bryan Burt, MD
COVID-19, Venous Thromboses
Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19
This study is being conducted to assess the effectiveness of intermediate versus prophylactic doses of anticoagulation (blood thinners) in patients critically ill with COVID-19 in the intensive care units (ICUs) throughout the…
- Conditions
- COVID-19, Venous Thromboses, Arterial Thrombosis
- Trial name
- IMPROVE (NCT04367831)
- Testing
- Enoxaparin Prophylactic Dose, Heparin Infusion, Heparin SC
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Columbia University
Covid19
The Prevent Severe COVID-19 (PRESECO) Study
Double-blinded, placebo control, randomized, phase-3 clinical trial to evaluate clinical efficacy of Favipiravir in patients with mild to moderate symptoms related to COVID-19 infection
- Trial name
- PRESECO (NCT04600895)
- Testing
- Favipiravir
- Where
- 38 sites in United States, Brazil and 1 more
- Volunteers
- 1,187 people
- Sponsor
- Appili Therapeutics Inc.
COVID-19
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
The purpose of this study is to learn about the side effects (safety) of the study medicine PF-07321332 (nirmatrelvir)/ritonavir for the treatment of mild to moderate COVID-19 infection in adults with severe renal impairment.
- Trial name
- NCT05487040
- Testing
- PF-07321332 (nirmatrelvir)/ritonavir
- Where
- 52 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Tachycardia, Dyspnea
Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study
Most patients with acute COVID-19 (Coronavirus 19) recover within weeks, however a significant number of individuals will develop the post-acute COVID 19 syndrome (PASC).
- Conditions
- Tachycardia, Dyspnea, COVID-19
- Trial name
- PEACE (NCT05096884)
- Testing
- Metoprolol Succinate
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Hackensack Meridian Health
Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome
Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS
The OLE study aims to investigate the safety, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod in participants with post-COVID-19 postural orthostatic.
- Trial name
- POTS (NCT05918978)
- Testing
- Efgartigimod
- Where
- 9 sites in United States
- Volunteers
- 33 people
- Sponsor
- argenx
COVID-19
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing acute respiratory failure in patients aged ≥65 and patients aged ≥18 with…
- Trial name
- Mir-Age (NCT04393038)
- Testing
- ABX464
- Where
- 30 sites in Belgium, Brazil and 6 more
- Volunteers
- 509 people
- Sponsor
- Abivax S.A.
COVID-19
Adaptive COVID-19 Treatment Trial 4 (ACTT-4)
ACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone and remdesivir. Subjects will be assessed daily while hospitalized.
- Trial name
- NCT04640168
- Testing
- Baricitinib, Dexamethasone, Remdesivir
- Where
- 72 sites in United States, Japan and 3 more
- Volunteers
- 1,010 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
This was a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose escalation and proof-of-concept study to evaluate the safety and efficacy of razuprotafib, administered 3 times daily (TID)…
- Trial name
- RESCUE (NCT04511650)
- Testing
- Razuprotafib Subcutaneous Solution
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Healthy
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants
This open-label, single dose study in approximately 5 healthy male and female (of non childbearing potential only) participants has been designed to characterize mass balance and further the understanding of human…
- Trial name
- NCT05050682
- Testing
- PF-07304814
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19, Sars-CoV2
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe…
- Conditions
- COVID-19, Sars-CoV2, Pneumonia
- Trial name
- NCT04463004
- Testing
- Mavrilimumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Virginia Commonwealth University
SARS (Severe Acute Respiratory Syndrome), Coronavirus
Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19
Severe acute respiratory syndrome (SARS-CoV2) due to novel Coronavirus (2019-nCoV) related infection (COVID-19) is characterized by severe ventilation perfusion mismatch leading to refractory hypoxemia.
- Trial name
- NOSARSCOVID (NCT04306393)
- Testing
- Nitric Oxide Gas
- Where
- 5 sites in United States, Sweden
- Volunteers
- 200 people
- Sponsor
- Massachusetts General Hospital
COVID-19
Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines
This study is a large-scale investigation (Phase 3) into a new booster shot designed specifically for teenagers. The booster targets a particular variant of COVID-19, Omicron XBB.1.5.
- Trial name
- COVID-19 (NCT05973006)
- Testing
- NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
- Where
- 20 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)
The purpose of the study is to determine if Liquid Alpha1-Proteinase Inhibitor (Human) (Liquid Alpha1-PI) plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day…
- Trial name
- NCT04547140
- Testing
- Liquid Alpha1-Proteinase Inhibitor (Human), Standard Medical Treatment
- Where
- 20 sites in United States, Brazil and 3 more
- Volunteers
- 57 people
- Sponsor
- Grifols Therapeutics LLC
Corona Virus Infection, Acute Respiratory Distress Syndrome
Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
Study Objective: 1. To test if post-exposure prophylaxis with hydroxychloroquine can prevent symptomatic COVID-19 disease after known exposure to the SARS-CoV-2 coronavirus. 2.
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection, Coronavirus
- Trial name
- COVID-19 PEP (NCT04308668)
- Testing
- Hydroxychloroquine
- Where
- 5 sites in United States, Canada
- Volunteers
- 1,312 people
- Sponsor
- University of Minnesota
Covid19
Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19
This is a phase 2 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 (Sotrovimab) Generation 1 (Gen1) or VIR-7831 (Sotrovimab) Generation 2 (Gen2) and will be assessed for safety, tolerability…
- Trial name
- COMET-PEAK (NCT04779879)
- Testing
- Sotrovimab (Gen1), Sotrovimab (Gen2)
- Where
- 31 sites in United States, Canada and 3 more
- Volunteers
- 354 people
- Sponsor
- Vir Biotechnology, Inc.
Depression, COVID-19
Effectiveness and Tolerability of аgomelatine in the Treatment of Patients With Depression After SARS-CoV-2 (TELESPHOR)
This is a multi-centre, observational, non-interventional study, which will prospectively collect clinical and socio-demographic data from patients with depression occurred after COVID 19 in real clinical settings during 8 weeks…
- Trial name
- TELESPHOR (NCT05323994)
- Where
- Russia
- Volunteers
- 104 people
- Sponsor
- Servier Russia
Covid19, SARS-CoV Infection
SARS-CoV-2 Human Challenge Characterisation Study
This is a dose optimisation study in healthy adults aged 18-30 who will be experimentally inoculated with SARS-CoV-2. The aim is to cause PCR-confirmed upper respiratory infection in the majority of challenged individuals with…
- Conditions
- Covid19, SARS-CoV Infection, Corona Virus Infection, Coronavirus
- Trial name
- NCT04865237
- Testing
- SARS-CoV-2 Virus 1x10^1 TCID50, Remdesivir, SARS-CoV-2 Virus 1x10^2 TCID50
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Covid19
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)
The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19.
- Trial name
- NCT05894577
- Testing
- Montelukast
- Where
- 109 sites in United States
- Volunteers
- 1,453 people
- Sponsor
- Susanna Naggie, MD